Asunercept

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Asunercept
Accession Number
DB15160
Description

Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).

Type
Biotech
Groups
Investigational
Synonyms
  • Asunercept
External IDs
  • APG101

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Asunercept.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Asunercept.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asunercept.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Asunercept.
AnsuvimabThe risk or severity of adverse effects can be increased when Asunercept is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Asunercept.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Asunercept.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asunercept.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Asunercept.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Asunercept.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
F333OQQ9UV
CAS number
1450882-18-4

References

General References
Not Available
Wikipedia
Asunercept

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19 Induced Pneumonia1
1CompletedTreatmentGlioblastoma Multiforme (GBM)1
1CompletedTreatmentMyelodysplastic Syndrome1
1, 2RecruitingTreatmentGlioblastoma, Adult1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 14:54 / Updated on February 21, 2021 18:55